Global Anticoagulants Market Outlook to 2020 – Demand for Patented NOACs with Prevalence of Cardiac Diseases to Drive Global Market” provides a comprehensive analysis of the anticoagulants market. The report includes the cumulative revenue generated by the market players from the sales of anticoagulants, including both generic and patented drugs at manufacturer’s price and market share contributed by the sales of heparin, NOACs, Vitamin K Antagonists, and Injectable Direct Inhibitors in the total anticoagulants market. Further, the market in the study is differentiated on the basis of route of administration into oral and injectable. The market is also segmented by four geographical regions across the globe – North America, Europe, Asia Pacific, and Rest of the World. Detailed snapshot on key regions of the Market which includes North America, Europe, and Asia Pacific is included in the report to elucidate facts about the market in detail. The study also highlights the detailed information about major drug manufacturers in the global anticoagulants market and their respective shares by revenue in 2015. Analysis on patented drugs available in the market, and their approval procedure, timeline, and expected expiries is provided in report to assist new entrants in understanding the market before investing in the market. Various marketing analysis factors such as trends and developments and Porter’s five forces analysis are also added in the study for clear understanding about the factors responsible for present scenario of the market. The future analysis of overall global anticoagulants market has also been discussed along with recommendations from analyst view.
Global Anticoagulants Market
Anticoagulants being the major part of the first line treatment of heart diseases including atrial fibrillation, deep vein thrombosis, pulmonary embolism, and stroke have been used extensively across the globe. Moreover, growing prevalence of coagulation disorders coupled with the aging population has increased the demand for anticoagulant drugs consequently leading to increased revenue generation. Launch of four patented drugs in the market in newly formed anticoagulants drug class, novel oral anticoagulants (NOACs) in between 2008 and 2014 has also resulted in high revenue generation for the total anticoagulants market as patented drugs are expensive in nature. Global anticoagulants market has been valued at USD ~ million in 2013 which increased to USD ~ million in 2015, exhibiting a CAGR of ~% in between 2013 and 2015.
Global Anticoagulants Market Segmentation
On the basis of type, heparin dominated the anticoagulants market with revenue share of ~% in 2015. Application of the heparin in wide therapeutic indications including venous thromboembolism, extracorporeal circuit procedure, and treatment of disseminated intravascular coagulation is the major factor which has led to the domination of heparin in the market. NOACs followed the heparin market in the global anticoagulants market with revenue share of ~% in 2015. The segment is also estimated as the fastest growing segment in the market. Flexibility to consume the drugs orally in comparison to injectables coupled with the presence of patented drugs in the market is the major factor which has driven the market for NOACs globally. Among the four patented drugs available in the NOAC category in the market, Bayer’s Xarelto has been observed to generate maximum sales providing company domination over other players.
By route of administration, injectable anticoagulants dominated the anticoagulants market with revenue share of ~% in 2015 owing to the availability of heparins and direct inhibitors in injectable state only. Heparins being oldest type of anticoagulants known are approved in all countries across the globe, which is one of the major factors driving the market for injectable anticoagulants. However, the segment is slowly losing revenue share owing to the increasing demand for oral anticoagulants due to ease of consumption and effective results.
By geographical regions, North America dominated the market with revenue share of ~% in 2015. High prevalence of coagulation disorders including atrial fibrillation, DVT and PE, presence of pharmaceutical giants, high awareness among people and economic stability to undergo expensive treatment options are the major factors which have driven the anticoagulants market in North America. Centers for Disease Control and Prevention estimated that approximately ~ to ~ million people in the US had atrial fibrillation in 2015 and with aging population, number is expected to increase. The statistics clearly advocates the high demand for anticoagulants in the region. Asia Pacific is estimated as the most opportunistic region in the market. High population in the country coupled with rising awareness and purchasing power of the people especially in India and China is assisting the region to grow at a rapid pace.
Competitive Scenario
Bayer dominated the global anticoagulants market in 2015 with revenue share of ~% in 2015. The advantage of owning the oldest type of patented NOAC, Xarelto in the market resulting in associated trust factor with the drug is the major factor which has helped the company in gaining high revenue share in the market. Sanofi with its Lovenox or Clexane in LMWH category captures second position in the market with revenue share of ~% in 2015. High popularity of the drug with wide patient pool of almost ~ million patients in more than 100 countries is the major factor which has helped company in generating high revenue in the market.
Key Topics Covered in the Report:
- The market size of Global Anticoagulants Market
- Market segmentation of Global Anticoagulants Market on the basis of Type, Route of Administration, and Geographical Analysis
- Snapshot on North America Anticoagulants Market
- Snapshot on Europe Anticoagulants Market
- Snapshot on Asia Pacific Anticoagulants Market
- Porter’s Five Forces Analysis for Global Anticoagulants Market
- Trends and Developments in Global Anticoagulants Market
- NOACs Drug Approval Timeline
- NOACs Patent Expiries
- Competitive Landscape and Detailed Company Profiles of the Major Market Players
- Future Outlook and Projections of Global Anticoagulants Market
- Analyst Recommendations
- Macro-Economic Factors Impacting the Global Anticoagulants Market
Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
Ankur@kenresearch.com
+91-9015378249
